Audeara's first half earnings loss was well flagged through updates and reflects accelerating key growth hires and positioning ahead of the large US opportunity, Morgans notes.

The key highlight was growth in the company's lead indicator of clinic numbers of 65% year on year, which now sees Audeara's products stocked in all major audiology clinics in Australia.

The company also achieved its first sales in the US through its distribution partnership, and continues to progress its US expansion with a significant opportunity in its leading products, the broker notes. Speculative Buy and 33c targe retained.

Sector: Consumer Durables & Apparel.

Target price is $0.33.Current Price is $0.12. Difference: $0.21 - (brackets indicate current price is over target). If AUA meets the Morgans target it will return approximately 64% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2022 Acquisdata Pty Ltd., source FN Arena